124 related articles for article (PubMed ID: 17099400)
1. Radiation safety implications of 131I treatment in a patient with Grave's disease undergoing home hemodialysis.
Simpson JB; Godwin GA
Health Phys; 2006 Dec; 91(6):570-3. PubMed ID: 17099400
[TBL] [Abstract][Full Text] [Related]
2. Radiation safety protocol for high dose 131I therapy of thyroid carcinoma in patients on hemodialysis for chronic renal failure.
Modarresifar H; Almodovar S; Bass WB; Ojha B
Health Phys; 2007 Feb; 92(2 Suppl):S45-9. PubMed ID: 17228187
[TBL] [Abstract][Full Text] [Related]
3. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
4. External dose rates in radioiodine treatment of benign goitre: estimation versus direct measurement.
Jørgensen HB; Høilund-Carlsen PF; Nielsen VE
Scand J Clin Lab Invest; 2006; 66(6):509-16. PubMed ID: 17000558
[TBL] [Abstract][Full Text] [Related]
5. The effects of a custom-made lead collar on dose rates of patients treated with 131I.
Stapel AG; van der Zant FM; Gommans GM; Boer RO; Reigman HI
Health Phys; 2009 May; 96(5 Suppl 2):S64-8. PubMed ID: 19359844
[TBL] [Abstract][Full Text] [Related]
6. Radiation safety considerations for post-iodine-131 hyperthyroid therapy.
Culver CM; Dworkin HJ
J Nucl Med; 1991 Jan; 32(1):169-73. PubMed ID: 1988627
[TBL] [Abstract][Full Text] [Related]
7. Iodine-131 pharmacokinetics in patients on hemodialysis for end stage renal disease: clinical implications.
Courbon F; Caselles O; Zerdoud S; Duthil P; Regis H; Berry I; Caron P
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):363-70. PubMed ID: 17043635
[TBL] [Abstract][Full Text] [Related]
8. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
de Carvalho JW; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
Nucl Med Commun; 2009 Jul; 30(7):533-41. PubMed ID: 19436231
[TBL] [Abstract][Full Text] [Related]
9. [Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 2: Therapeutic procedures].
Sudbrock F; Boldt F; Kobe C; Hammes J; Eschner W; Schicha H
Nuklearmedizin; 2009; 48(1):17-25. PubMed ID: 19212607
[TBL] [Abstract][Full Text] [Related]
10. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
11. Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy.
Marriott CJ; Webber CE; Gulenchyn KY
Radiat Prot Dosimetry; 2007; 123(1):62-7. PubMed ID: 16825250
[TBL] [Abstract][Full Text] [Related]
12. Correlation between external exposure and activity in patients undergoing 131I thyroid cancer therapy.
Barquero R; Basurto F; Vega-Carrillo HR; Iñiguez MP; Ferrer N; Esteban R
Health Phys; 2008 Aug; 95(2):227-33. PubMed ID: 18617804
[TBL] [Abstract][Full Text] [Related]
13. Estimating radiation absorbed dose of individuals nearby 131I-treated hyperthyroid patients.
Cui S; Jiao L; Tan J; Zhang G; Zhang H; Long W; Fan S; Zhang W
Health Phys; 2014 Mar; 106(3):365-9. PubMed ID: 25208013
[TBL] [Abstract][Full Text] [Related]
14. Clearance of 131I by hemodialysis.
Culpepper RM; Hirsch JI; Fratkin MJ
Clin Nephrol; 1992 Aug; 38(2):110-4. PubMed ID: 1516279
[TBL] [Abstract][Full Text] [Related]
15. Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma.
Dauer LT; St Germain J; Williamson MJ; Zanzonico P; Modak S; Cheung NK; Divgi C
Health Phys; 2007 Jan; 92(1):33-9. PubMed ID: 17164597
[TBL] [Abstract][Full Text] [Related]
16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
17. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
El Refaei SM; Shawkat W
Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
[TBL] [Abstract][Full Text] [Related]
18. Work to save dose: contrasting effective dose rates from radon exposure in workplaces and residences against the backdrop of public and occupational regulatory limits.
Whicker JJ; McNaughton MW
Health Phys; 2009 Sep; 97(3):248-56. PubMed ID: 19667808
[TBL] [Abstract][Full Text] [Related]
19. Release criteria from hospitals of 131I thyrotoxicosis therapy patients in developing countries--case study.
Muhammad W; Faaruq S; Matiullah ; Hussain A; Khan AA
Radiat Prot Dosimetry; 2006; 121(2):136-9. PubMed ID: 16464838
[TBL] [Abstract][Full Text] [Related]
20. [Hemodialysis procedure in a patient treated with radioactive iodine].
Brunet P; Bourrelly M; Mundler O; Bouvier C; Faure V; Opris A; Bouchouareb D; Indreies M; Ramananarivo P; Dussol B; Berland Y
Nephrol Ther; 2008 Jun; 4(3):196-201. PubMed ID: 18272443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
